Shire

Shire
Share

Shire

 •  January 15

Marketing Authorization will enable patient access to ADYNOVI throughout Europe Zug, Switzerland – January 15, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant),...

Shire

 •  December 27, 2017

Dublin, Ireland – December 27, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that it has filed its first submission to the United States Food and Drug Administration for the company’s new plasma manufacturing facility in Covington, Georgia. The facility is expected to add approximately...

Shire

 •  December 19, 2017

First and only FDA-cleared PK dosing software to support healthcare professionals in creating personalized dosing regimens for patients 16 and older with hemophilia A1 myPKFiT for ADVATE software availability planned for end of Q1 2018 Cambridge, Ma. – December 19, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare...

Shire

 •  December 19, 2017

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced top-line results from its Phase II/III clinical trial evaluating SHP609, previously known as HGT-2310. SHP609 is an investigational formulation of idursulfase administered intrathecally for a new potential indication for the treatment of pediatric patients...

Shire

 •  December 14, 2017

Cambridge, MA – December 14, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, RCSI (Royal College of Surgeons Ireland ), and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, today jointly announced the initiation of a novel clinical study called “The Irish Personalised...

Shire

 •  November 6, 2017

Research to be presented at IPIC 2017 Annual Scientific Meeting, reinforcing Shire’s commitment to help patients living with primary immunodeficiency Zug, Switzerland – November 6, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today new data from the company’s primary...

Shire

 •  October 26, 2017

FIRAZYR is the first and only subcutaneous treatment in Europe for acute HAE attacks approved for children aged 2 years and older
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR®...

Shire

 •  October 23, 2017

Research to be presented at ACAAI 2017 Annual Scientific Meeting, reinforcing Shire’s commitment to help patients living with hereditary angioedema and primary immunodeficiency Cambridge, MA – Oct 23, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, announced today new data from the company’s hereditary...

Shire

 •  July 9, 2017

Berlin, Germany – July 9 2017 - Shire International GmbH has obtained a preliminary injunction in a court of Hamburg, Germany against F. Hoffmann-La Roche Ltd. (Roche) to address incomplete and misleading statements that may impact important issues of patient safety regarding the investigational treatment emicizumab. Under the injunction, Shire...

Shire

 •  April 26, 2017

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism Zug, Switzerland - April 26, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the first recombinant human protein...